This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

CytRx Corporation (CYTR) Showing Signs Of A Dead Cat Bounce Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified CytRx Corporation ( CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified CytRx Corporation as such a stock due to the following factors:

  • CYTR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $22.2 million.
  • CYTR has traded 611,940 shares today.
  • CYTR is up 3.5% today.
  • CYTR was down 8.5% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CYTR with the Ticky from Trade-Ideas. See the FREE profile for CYTR NOW at Trade-Ideas

More details on CYTR:

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs, aldoxorubicin and tamibarotene, which are in clinical development for cancer indications.

The average volume for CytRx Corporation has been 4.1 million shares per day over the past 30 days. CytRx has a market cap of $277.0 million and is part of the health care sector and drugs industry. The stock has a beta of 1.47 and a short float of 20% with 1.79 days to cover. Shares are down 3.7% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates CytRx Corporation as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, weak operating cash flow and feeble growth in its earnings per share.

Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 730.0% when compared to the same quarter one year ago, falling from $1.58 million to -$9.98 million.
  • The gross profit margin for CYTRX CORP is currently extremely low, coming in at 0.00%. CYTR has continued with the weak profit margin when compared to the same quarter of last year.
  • Net operating cash flow has decreased to -$4.85 million or 10.25% when compared to the same quarter last year. Despite a decrease in cash flow CYTRX CORP is still fairing well by exceeding its industry average cash flow growth rate of -38.82%.
  • CYTRX CORP has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, CYTRX CORP reported poor results of -$0.91 versus -$0.84 in the prior year. This year, the market expects an improvement in earnings (-$0.81 versus -$0.91).
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, CYTRX CORP's return on equity significantly trails that of both the industry average and the S&P 500.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 16,353.37 -27.04 -0.17%
S&P 500 1,897.11 +10.35 0.55%
NASDAQ 4,295.6090 +37.1710 0.87%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs